Ipsen Secures Global Licensing Agreement for Biomunex Pharmaceuticals’ BMX-502 T Cell Engager
France-based Ipsen (OTCMKTS: IPSEY) has announced a significant global licensing agreement with compatriot firm Biomunex...
OncoC4, Inc. Receives FDA Clearance for AI-081, a PD-1 and VEGF Bispecific Antibody
US-based OncoC4, Inc. has announced that it has received clinical clearance from the US Food...
Luye Pharma’s Zepzelca Receives NMPA Approval for Metastatic Small Cell Lung Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from...
Sacituzumab Tirumotecan Earns FDA Breakthrough Therapy Designation for EGFR Mutated NSCLC
Sacituzumab tirumotecan (SKB264/MK-2870), a TROP2-targeted antibody drug conjugate (ADC) co-developed by Merck, Sharp & Dohme...
Merck’s Recarbrio Approved by NMPA for Hospital-Acquired Infections and Complicated UTIs
US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has announced that it...
Abbisko Therapeutics Gets FDA Green Light for Phase I Study of ABSK131 Inhibitor
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Hefan Medicine’s Piracetam Production and Marketing Suspended Over GMP Violations
The National Drug Alliance Procurement Office has issued a notification to suspend the manufacturing and...
InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) has announced the successful completion of a Phase...
Shanghai Henlius Biotech’s Serplulimab Approved for First-Line nsNSCLC Treatment in China
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced that it has received marketing approval from...
Zhejiang Huahai Pharmaceutical Initiates Clinical Study for HB0056 in New Zealand
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521), through its subsidiary Shanghai Huaota Biopharmaceutical Co., Ltd.,...
HutchMed and Innovent Biologics’ Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer
Chinese firms HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
Acotec Scientific’s AcoArt Camellia Receives NMPA Approval for Coronary Artery Disease Treatment
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...
REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia
Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San...
AccurEdit Therapeutics’ ART001 Shows Over 90% TTR Reduction in ATTR Amyloidosis Trial
Suzhou-based gene editing specialist AccurEdit Therapeutics has announced positive results from an ongoing investigator-initiated trial...
Sanofi Announces EUR 1 Billion Investment for New Beijing Manufacturing Plant
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced plans to invest EUR 1 billion (USD...
Huadong Medicine’s SaiYueXin Biosimilar Accepted for Review by NMPA for Pediatric Psoriasis
Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA)...
Jiangsu Hengrui Pharmaceuticals’ Fluzoparib and Apatinib Gain NMPA Approval for Metastatic Breast Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Fangzhou Inc. Expands Partnerships with Tencent Healthcare and Baidu Health at Digital Summit
China-based Fangzhou Inc. (HKG: 6086) hosted the “Data and AI: Decoding Digital Engagement” summit in...
MGI Tech Co., Ltd Partners with Universidad de San Martín de Porre for Genomic Sequencing Advancement
China-based gene sequencing specialist MGI Tech Co., Ltd has announced a collaboration with the Universidad...
VFLO Medical Partners with Inari Medical to Expand Access in Greater China
China-based VFLO Medical, a peripheral vascular device firm incubated by 6 Dimensions Capital, has announced...